By Gary M. White, MD

Balicatib has been studied in women to prevent loss of vertebral and femoral bone mineral density and to increase bone strength. During the trials, morphea-like changes of the skin occurred. As documented in one report [JAAD 2012;66;e89], nine patients of 709 treated with balicatib developed skin hardening. No such events were observed in patients taking placebo or the lowest balicatib dose. After discontinuation of balicatib, skin changes resolved completely in 8 and partially in one patient.


J Am Acad Dermatology Volume 66, Issue 3, Pages e89–e96, March 2012


Homepage | FAQs | Use of Images | Contact Dr. White

It is not the intention of RegionalDerm.com to provide specific medical advice, diagnosis or treatment. RegionalDerm.com only intends to provide users with information regarding various medical conditions for educational purposes and will not provide specific medical advice. Information on RegionalDerm.com is not intended as a substitute for seeking medical treatment and you should always seek the advice of a qualified healthcare provider for diagnosis and for answers to your individual questions. Information contained on RegionalDerm.com should never cause you to disregard professional medical advice or delay seeking treatment. If you live in the United States and believe you are having a medical emergency call 911 immediately.